Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout disease

Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout disease - Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029843

Enrollment

Registered

2017-11-06

Start date

2017-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory lymphangiomatosis, Gorham-Stout disease

Interventions

Oral sirolimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with refractory lymphangiomatosis, Gorham-Stout disease

Exclusion criteria

Exclusion criteria: Allergy of sirolimus

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptoms at every 1 month after administration	—

Countries

Japan

Contacts

Public ContactRyota SOUZAKI

Kyushu University Hospital Pediatric surgery

ryotas@med.kyushu-u.ac.jp092-642-5573

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026